Publications by authors named "Michela Cumerlato"
Article Synopsis
- Multiple myeloma (MM) is a serious illness where certain blood cells grow uncontrollably in the bone marrow, making it hard for patients to get better.
- Researchers found that a special type of RNA called NEAT1 helps these cancer cells grow, making it a potential target for new treatments.
- They discovered that combining NEAT1 blockage with a specific drug called AURKA inhibitors could kill these cancer cells more effectively, especially since high levels of both NEAT1 and AURKA are linked to worse health outcomes in patients.
Background: Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and disease progression remain common. Therefore, a major challenge is the development of novel therapeutic approaches to overcome drug resistance, improve patient outcomes, and broaden PIs applicability to other pathologies.
View Article and Find Full Text PDFArticle Synopsis
- Proteasome inhibitors (PIs) are used to treat multiple myeloma, but many patients either relapse or don’t respond well to them.
- A study found that combining a drug called UNC0642 with another treatment called carfilzomib can work better against multiple myeloma, even in tough cases.
- The research suggests that blocking a protein called EHMT2 could help make these treatments more effective and might help find new ways to overcome resistance to the drugs.
Ectopic expression of RUNX2 has been reported in several tumors. In melanoma cells, the RUNT domain of RUNX2 increases cell proliferation and migration. Due to the strong link between RUNX2 and skeletal development, we hypothesized that the RUNT domain may be involved in the modulation of mechanisms associated with melanoma bone metastasis.
View Article and Find Full Text PDF